Abstract
Ganglioside treatment was evaluated with a multicenter, randomized, double-blind, controlled, cross-over vs placebo trial in 140 insulin-treated diabetic subjects with peripheral neuropathy. The patients entered the study when they showed an impairment in at least two of the electroneurographic parameters, and were assigned to two protocols according to the presence and severity of their neurological symptoms. Ninety-seven diabetic subjects with no or mild symptoms were assigned to protocol I, whereas 43 symptomatic patients were assigned to protocol II. The treatment periods lasted 6 weeks with an intermediate washout period of 4 weeks. The treatment consisted in the daily i.m. administration of 20 mg gangliosides or of placebo. Electroneurographic parameters were recorded at the beginning and at the end of each treatment period, whereas clinical and metabolic data (mean daily plasma glucose, glycosuria and glycosylated hemoglobin) were evaluated every three weeks in protocol I and every two weeks in protocol II. No change in the metabolic parameters was observed throughout the trial period. However, the treatment induced a statistically significant improvement of paresthesias (protocol II) and of some electrophysiological parameters; in particular, ganglioside treatment improved MCV of peroneal nerve (p
| Original language | English |
|---|---|
| Pages (from-to) | 265-276 |
| Number of pages | 12 |
| Journal | Acta Diabetologica Latina |
| Volume | 20 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Jul 1983 |
Fingerprint
Keywords
- Diabetic neuropathy
- Gangliosides
- Nerve conduction velocity
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
- Endocrinology
Cite this
Ganglioside treatment in diabetic peripheral neuropathy : A multicenter trial. / Crepaldi, Gaetano; Fedele, Domenico; Tiengo, Antonio; Battistin, Leontino; Negrin, Paolo; Pozza, Guido; Canal, Nicola; Comi, Gian Carlo; Lenti, Gianfranco; Pagano, Gianfranco; Bergamini, Ludovico; Troni, Walter; Frigato, Francesco; Ravenna, Cesare; Mezzina, Corrado; Gallato, Roberta; Massari, Danilo; Massarotti, Marino; Matano, Rita; Grigoletto, Francesco; Davis, Hank; Klein, Monroe.
In: Acta Diabetologica Latina, Vol. 20, No. 3, 07.1983, p. 265-276.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Ganglioside treatment in diabetic peripheral neuropathy
T2 - A multicenter trial
AU - Crepaldi, Gaetano
AU - Fedele, Domenico
AU - Tiengo, Antonio
AU - Battistin, Leontino
AU - Negrin, Paolo
AU - Pozza, Guido
AU - Canal, Nicola
AU - Comi, Gian Carlo
AU - Lenti, Gianfranco
AU - Pagano, Gianfranco
AU - Bergamini, Ludovico
AU - Troni, Walter
AU - Frigato, Francesco
AU - Ravenna, Cesare
AU - Mezzina, Corrado
AU - Gallato, Roberta
AU - Massari, Danilo
AU - Massarotti, Marino
AU - Matano, Rita
AU - Grigoletto, Francesco
AU - Davis, Hank
AU - Klein, Monroe
PY - 1983/7
Y1 - 1983/7
N2 - Ganglioside treatment was evaluated with a multicenter, randomized, double-blind, controlled, cross-over vs placebo trial in 140 insulin-treated diabetic subjects with peripheral neuropathy. The patients entered the study when they showed an impairment in at least two of the electroneurographic parameters, and were assigned to two protocols according to the presence and severity of their neurological symptoms. Ninety-seven diabetic subjects with no or mild symptoms were assigned to protocol I, whereas 43 symptomatic patients were assigned to protocol II. The treatment periods lasted 6 weeks with an intermediate washout period of 4 weeks. The treatment consisted in the daily i.m. administration of 20 mg gangliosides or of placebo. Electroneurographic parameters were recorded at the beginning and at the end of each treatment period, whereas clinical and metabolic data (mean daily plasma glucose, glycosuria and glycosylated hemoglobin) were evaluated every three weeks in protocol I and every two weeks in protocol II. No change in the metabolic parameters was observed throughout the trial period. However, the treatment induced a statistically significant improvement of paresthesias (protocol II) and of some electrophysiological parameters; in particular, ganglioside treatment improved MCV of peroneal nerve (p
AB - Ganglioside treatment was evaluated with a multicenter, randomized, double-blind, controlled, cross-over vs placebo trial in 140 insulin-treated diabetic subjects with peripheral neuropathy. The patients entered the study when they showed an impairment in at least two of the electroneurographic parameters, and were assigned to two protocols according to the presence and severity of their neurological symptoms. Ninety-seven diabetic subjects with no or mild symptoms were assigned to protocol I, whereas 43 symptomatic patients were assigned to protocol II. The treatment periods lasted 6 weeks with an intermediate washout period of 4 weeks. The treatment consisted in the daily i.m. administration of 20 mg gangliosides or of placebo. Electroneurographic parameters were recorded at the beginning and at the end of each treatment period, whereas clinical and metabolic data (mean daily plasma glucose, glycosuria and glycosylated hemoglobin) were evaluated every three weeks in protocol I and every two weeks in protocol II. No change in the metabolic parameters was observed throughout the trial period. However, the treatment induced a statistically significant improvement of paresthesias (protocol II) and of some electrophysiological parameters; in particular, ganglioside treatment improved MCV of peroneal nerve (p
KW - Diabetic neuropathy
KW - Gangliosides
KW - Nerve conduction velocity
UR - http://www.scopus.com/inward/record.url?scp=0021090813&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021090813&partnerID=8YFLogxK
U2 - 10.1007/BF02581271
DO - 10.1007/BF02581271
M3 - Article
C2 - 6356740
AN - SCOPUS:0021090813
VL - 20
SP - 265
EP - 276
JO - Acta Diabetologica
JF - Acta Diabetologica
SN - 0940-5429
IS - 3
ER -